We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Kanabo Group Plc | LSE:KNB | London | Ordinary Share | GB00BYQCS703 | ORD 2.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.90 | 600,076 | 08:00:03 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.80 | 1.00 | 0.90 | 0.839 | 0.90 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 895k | -7.99M | -0.0126 | -0.71 | 5.69M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 14:54:47 | O | 124,239 | 0.821 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/11/2024 | 09:55 | UK RNS | Kanabo Group PLC The GP Service Wins Award |
| 31/10/2024 | 09:48 | UK RNS | Kanabo Group PLC Correction Director/PDMR Shareholding |
| 29/10/2024 | 11:39 | UK RNS | Kanabo Group PLC Director/PDMR Shareholding |
| 30/9/2024 | 13:50 | UK RNS | Kanabo Group PLC Half-year Report |
| 28/8/2024 | 13:31 | UK RNS | Kanabo Group PLC Director/PDMR Shareholding |
| 27/6/2024 | 15:49 | UK RNS | Kanabo Group PLC Result of AGM |
| 04/6/2024 | 06:00 | UK RNS | Kanabo Group PLC Expansion:14 New Clinics Partnership with Treat-It |
| 31/5/2024 | 09:30 | UK RNS | Kanabo Group PLC Notice of AGM |
| 30/4/2024 | 13:15 | UK RNS | Kanabo Group PLC Annual Financial Report |
| 28/3/2024 | 07:00 | UK RNS | Kanabo Group PLC Expansion of Treat It to Mental Health Treatments |
Kanabo (KNB) Share Charts1 Year Kanabo Chart |
|
1 Month Kanabo Chart |
Intraday Kanabo Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 06/12/2024 | 12:48 | Kanabo Group Medicinal Cannabis | 1,832 |
| 13/6/2023 | 08:22 | KANABO - Riding the Cannabis Wave | 22 |
| 25/2/2021 | 15:34 | Kanobo Warrants | 4 |
| 15/2/2021 | 13:05 | Kanabo Group Medicinal Cannabis | 2 |
| 17/8/2009 | 16:18 | Kinbauri Gold: Alive and Kicking | 26 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 14:54:48 | 0.82 | 124,239 | 1,020.00 | O |
| 14:36:53 | 0.80 | 31 | 0.25 | O |
| 14:08:36 | 1.00 | 56 | 0.56 | O |
| 13:32:20 | 0.85 | 10,000 | 85.10 | O |
| 12:07:22 | 0.81 | 2,829 | 22.77 | O |
| Top Posts |
|---|
Posted at 20/12/2024 08:20 by Kanabo Daily Update Kanabo Group Plc is listed in the Medical Laboratories sector of the London Stock Exchange with ticker KNB. The last closing price for Kanabo was 0.90p.Kanabo currently has 632,427,870 shares in issue. The market capitalisation of Kanabo is £5,691,851. Kanabo has a price to earnings ratio (PE ratio) of -0.71. This morning KNB shares opened at 0.90p |
Posted at 06/12/2024 12:48 by 1chrism What a reference; equal parts observant and hilarious. We unfortunately have no option but to hope the CE mark comes in before the ever decreasing spiral sees KNB hitting the deck |
Posted at 03/12/2024 18:25 by bobea I'm beginning to think this share has turned into an oozlum bird |
Posted at 04/11/2024 17:47 by bobea I realise that they are not the same type of company but the point is both companies share price has collapsed.Yes Kanabo have increased revenue but are still running at a loss, so unless something dramatically changes fairly soon they will need more money. At this price will not do holders any good. I believe Kanabo floated at about 6p and is now less than 1p. I honestly believe the only way is to delist and get private funding on true value not value based on share price. |
Posted at 23/10/2024 07:09 by 1chrism KNB have a £700k stake in HELD. However, their is a significant difference to the other cannibis companies you mention. KNB are farm to pharmacy with expanding revenue. What holds the company back is the wait for CE mark approval of their vape pen. |
Posted at 22/10/2024 21:18 by bobea I believe KNB had a stake in HELD who's shares were suspended after a crash in share price.🤔 |
Posted at 22/10/2024 20:59 by bobea Thought this company was different to cbx and mgc but it will probably do the same and change its name and wipe out existing share holders.maybe this was the plan all along either way it's not coming back from this. |
Posted at 17/7/2023 07:10 by oakridge Comment from the HELD thread on this RNS by KNB this morning:Oakridge17 Jul '23 - 07:49 - 1049 of 1049 Edit 0 1 0 An interesting RNS at KNB this morning that is worth comparing and contrasting with HELD. Their partly owned (40%) subsidiary, Agritec, has a contract to develop a cannabis production site in Spain. They are a predicted 24 months away (yes - approx two years away) from being able to produce 3000kg annually...of which they will only have a partial share.....and that's if all goes to plan. I suspect a soft response by the mkt. Their CEO is very upbeat about this however and believes it will deliver significant revenues and shareholder value. Whilst it is good news for their own supply chain, the above figure and time lines help bring some sweeping perspective as to just how large HELD *could* become and where we are in respect of timing... HELD's license is good for 55,000kg annually and a site that can be incrementally scaled to match the size of that license. The bunkers (already built) that HELD intends using first are good for 1000kg, with further expansion across the site via POD agreements, the first of which should be via Demecan.... We were recently told that we were on schedule for the first cropping this quarter and we were also told further PODS were in the pipeline..... KNB's apparent enthusiasm for their partly owned 3000kg in approx 24 months brings some useful contrast to where HELD apparently are, I feel. A lot can happen in two years, but its reassuring to think KNB are taking that route with a 24 month window, growing to that fairly limited scale and in a country that will likely have higher costs than Greece. A few checkpoints still to be cleared at HELD of course as well as the clean execution and sale of our first crop......but should that happen and we get to see POD agreements arriving and being implemented, I should think it will inspire the market somewhat. We'll see. AIMO ADYOR etc. |
Posted at 27/1/2023 10:50 by oakridge idlejack - you might well be correct re. HELD.I have now written pretty extensively about that stock and its current predicament....parti As I have tried to explain (perhaps unsuccessfully) to someone only last night: "you are wrong to automatically ASSUME that a falling share price in the meantime is necessarily bad news for those looking to build a position, add or enter the fray". The weakness at HELD will certainly be uncomfortable for those who are 'all in' and who are in any way unsure about their investment rationale or timelines. But for those who have some form of confidence in the business, or at least believe in the narrative that it will soon be cash generative and meaningfully so, the current weakness and seller in the mkt could be seen as presenting something of an opportunity - especially for those with dry powder. HELD carries risk and uncertainty of course and is in no way a guaranteed winning ticket (at any price). KNB, due to its earlier arrival (launching into the heady highs of the cannabis sentiment) and relatively slow progress since, is somewhat more advanced along the 'curve of disappointment'..... It goes entirely against human nature to be drawn to weak share prices and poor sentiment and especially because of the woeful year many cannabis stocks have just had specifically, there is likely to be more than a little cynicism washing around in the space. However I believe 2023 will be the year where some confidence returns to the sector as a whole. As ever, it will be about picking the right ones for the right reasons and at the right prices. AIMO and ADYOR. |
Posted at 26/1/2023 11:20 by wageslave HELD is tanking today. Perhaps that's impacting on KNB share price. |
Posted at 26/1/2023 07:50 by oakridge A good rise off the recent lows here yesterday and supported by the third largest upswing in volume since early 2021.We have watched KNB from the sidelines for well over a year and since around the time of their strategic investment into Hellenic Dynamics (HELD), which came to market in early December '22 via an RTO and only after a protracted period of regulatory approval. As peeps here should all know, HELD are cultivators with facilities in located in Greece who are targeting the European market, including the UK, with term sheets already signed for supply into Germany. Initial sales are anticipated in Q2 of this year. We already hold some shares in HELD but are trying to build a meaningful position there during the current phase of weakness in the share price. This has been aided by a seller in the market together with the likely leave of 'legacy holders' (ie those who were invested in an unrelated company prior to the suspension and RTO), and who are perhaps not aligned with the resulting company and its future. We have also, finally, become recent and modest buyers of KNB. Aside from KNB's material interest in HELD, the two companies have both some differentiation and overlap. KNB listed into a period of great enthusiasm in respect of the THC space whilst HELD, due to regulatory hurdles and delays surrounding its pioneering status as first cultivator with a main listing, was much later in its arrival. This delay has been a mixed blessing. Whilst the space cooled considerably in 2022, the future and underlying demand for medicinal cannabis, at this stage at least, appears to have only strengthened. Many other THC stocks reveal a similar woeful 2022 to that of KNB, trading at a mere fraction of where they were when medicinal cannabis was very much the darling of the moment. The space is still early stage and, in my view, underserved in that it is still very much evolving and defining itself (both on the regulatory front and in terms of adoption and acceptance). There are now 25 countries in the EU who allow THC dominant medical prescriptions and that number has grown only very recently and continues to grow. In the UK specifically (which sees one of the worst opioid addiction/dependence issues Europe) the market for THC grew by 425% in 2021 alone. The predicted growth rates for Germany over the next five years - a comparatively mature, but still very early stage market - are also impressive. The space is certainly not without its challenges and obstacles, but whilst many cannabis stocks have had an extremely poor 2022, the actual space itself would seem undiminished. Therefore I think as things open up, and by that I mean through greater adoption and the potential for supportive clinical findings (we are due some in the UK specifically in March) we may begin to see some disconnect emerge between market traction and company valuations and potential. I will continue to monitor both companies and it will be interesting to see if 2023 is the year which sees a welcome return of favour to this sector as a whole. I think there's a reasonable chance that's on the cards. AIMO only and NAI. ADYOR etc. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
